The effect of vitamin D on nonspecific low back pain
International Journal of Rheumatic Diseases, Volume 18, Issue 8, pages 854–858, November 2015
Mahnaz Sandoughi 1, Zahra Zakeri 1,*, Zahra Mirhosainee 1, Mahdi Mohammadi 2 and Sogol Shahbakhsh 3
Randomized Controlled Trial
Vitamin D level 18 ng ==> 28 ng
Similar reduction in back pain for VitD and placebo
Vitamin D Life expects that vitamin D levels would have gotten much higher and back pain would have been relieved if trial had been 12 weeks instead of just 8 weeks
Alternatively, expect a good response in just 3 weeks if had started with a loading dose of vitamin D: 50,000 IU daily for 7 days.
See also Vitamin D Life
Intervention - Vitamin D has 237 SUCCESSFUL intervention studies
-when enough vitamin D was given
Download the PDF from Vitamin D Life
Background
Nonspecific low back pain is known as one of the most common reasons for chronic low back pain (CLBP) that burdens healthcare systems with high costs. According to a hypothesis, CLBP has been associated with vitamin D3 deficiency, the goal of this study is to evaluate the effect of vitamin D3 administration on improvements in CLBP.
Materials and Methods
This double blind randomized clinical trial included 53 patients aged between 18–40 years with nonspecific CLBP. Pain was measured using the pain visual analogue scale score (VAS), and serum 25-OH-vitamin D level was measured using an enzyme-linked immunosorbent assay kit. The patients were randomly divided into two groups based on sex and weight. Pearl of vitamin D3 (50 000 IU) or placebo was administered orally every week for 8 weeks. Data were analyzed via SPSS 17th edition software using two-tailed paired t-test and chi-square test.
Results
There were 26 and 27 patients in drug and placebo groups respectively. Out of 53 subjects, 75.47% were female. There was no statistically significant difference in the mean age, sex, and mean weight between the two groups. The mean serum 25-OH-vitamin D level was 18.86 ± 9.24 nmol/L on the first visit. After 8 weeks of intervention, the mean serum 25-OH-vitamin D level changed from 17.88 ± 9.04 to 27.52 ± 9.04 (P = 0.043) and from 19.81 ± 9.60 to 18.91 ± 7.84 (P = 0.248) in drug and placebo groups, respectively. The mean VAS score for pain decreased from 5.42 ± 1.65 to 3.03 ± 3.14 (P = 0.001) and from 6.42 ± 1.62 to 3.11 ± 3.08 (P = 0.001) among drug and placebo groups, respectively. The mean changes in chronic pain were 2.38 ± 2.62, 95% confidence interval (CI) = 1.32–3.44 in the drug group and 3.33 ± 3.67, 95%CI = 0.61–2.55 in the placebo group. No significant statistical difference between the two groups was observed.
Conclusion
According to our results, both vitamin D3 and placebo treatments improved CLBP and there was no significant difference between vitamin D3 and placebo groups.